Zuzana Potacova

Publications
CV
Public outreach and news

Articles

Article: JOURNAL OF IMMUNOTHERAPY. 2017;40(4):132-139

A Preliminary Report: Radical Surgery and Stem Cell Transplantation for the Treatment of Patients With Pancreatic Cancer.

Omazic B; Ayoglu B; Löhr M; Segersvärd R; Verbeke C; Magalhaes I; Potacova Z; Mattsson J; Terman A; Ghazi S; Albiin N; Kartalis N; Nilsson P; Poiret T; Zhenjiang L; Heuchel R; Schwenk JM; Permert J; Maeurer MJ; Ringden O
Article: PLOS ONE. 2017;12(11):e0187294

Flavin-containing monooxygenase 3 (FMO3) role in busulphan metabolic pathway.

El-Serafi I; Terelius Y; Abedi-Valugerdi M; Naughton S; Saghafian M; Moshfegh A; Mattsson J; Potácová Z; Hassan M
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2016;22(4):676-681

Long-Term Follow-Up of Allogeneic Hematopoietic Stem Cell Transplantation for Solid Cancer.

Omazic B; Remberger M; Barkholt L; Söderdahl G; Potácová Z; Wersäll P; Ericzon B-G; Mattsson J; Ringdén O
Article: TOXICOLOGY IN VITRO. 2015;29(7):1711-1719

Copper-based nanoparticles induce high toxicity in leukemic HL60 cells.

Rodhe Y; Skoglund S; Odnevall Wallinder I; Potácová Z; Möller L
Article: PHARMACOGENOMICS JOURNAL. 2015;15(5):405-413

Cytochrome P450 2J2, a new key enzyme in cyclophosphamide bioactivation and a potential biomarker for hematological malignancies.

El-Serafi I; Fares M; Abedi-Valugerdi M; Afsharian P; Moshfegh A; Terelius Y; Potácová Z; Hassan M
Article: BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. 2015;463(3):268-274

DNA damage, lysosomal degradation and Bcl-xL deamidation in doxycycline- and minocycline-induced cell death in the K562 leukemic cell line.

Fares M; Abedi-Valugerdi M; Hassan M; Potácová Z
Article: PLOS ONE. 2014;9(12):e114457

Cytotoxic effects of tetracycline analogues (doxycycline, minocycline and COL-3) in acute myeloid leukemia HL-60 cells.

Song H; Fares M; Maguire KR; Sidén A; Potácová Z
Article: PLOS ONE. 2014;9(1):e86619

Cyclophosphamide alters the gene expression profile in patients treated with high doses prior to stem cell transplantation.

El-Serafi I; Abedi-Valugerdi M; Potácová Z; Afsharian P; Mattsson J; Moshfegh A; Hassan M
Article: BONE MARROW TRANSPLANTATION. 2013;48(6):843-848

Omega-3 from fish oil augments GVHD through the enhancement of chemotherapy conditioning regimen and selective FoxP3 depletion.

Al Hashmi S; Sadeghi B; Hassan Z; Abedi-Valugerdi M; Lindskog M; Hassan M
Article: BONE MARROW TRANSPLANTATION. 2013;48(2):284-293

Early-phase GVHD gene expression profile in target versus non-target tissues: kidney, a possible target?

Sadeghi B; Al-Chaqmaqchi H; Al-Hashmi S; Brodin D; Hassan Z; Abedi-Valugerdi M; Moshfegh A; Hassan M
Article: JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES. 2013;913-914:98-105

Gas chromatographic-mass spectrometry method for the detection of busulphan and its metabolites in plasma and urine.

El-Serafi I; Terelius Y; Twelkmeyer B; Hagbjörk A-L; Hassan Z; Hassan M
Article: PLOS ONE. 2012;7(1):e30897

Busulphan-cyclophosphamide cause endothelial injury, remodeling of resistance arteries and enhanced expression of endothelial nitric oxide synthase.

Al-Hashmi S; Boels PJM; Zadjali F; Sadeghi B; Sällström J; Hultenby K; Hassan Z; Arner A; Hassan M
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2011;17(11):1688-1697

Improved survival after allogeneic hematopoietic stem cell transplantation in recent years. A single-center study.

Remberger M; Ackefors M; Berglund S; Blennow O; Dahllöf G; Dlugosz A; Garming-Legert K; Gertow J; Gustafsson B; Hassan M; Hassan Z; Hauzenberger D; Hägglund H; Karlsson H; Klingspor L; Kumlien G; Le Blanc K; Ljungman P; Machaczka M; Malmberg K-J; Marschall H-U; Mattsson J; Olsson R; Omazic B; Sairafi D; Schaffer M; Svahn B-M; Svenberg P; Swartling L; Szakos A; Uhlin M; Uzunel M; Watz E; Wernerson A; Wikman A; Wikström A-C; Winiarski J; Ringdén O
Article: INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY. 2011;4(6):596-605

Dynamics of early histopathological changes in GVHD after busulphan/cyclophosphamide conditioning regimen.

Al-Hashmi S; Hassan Z; Sadeghi B; Rozell B; Hassan M
Article: SULTAN QABOOS UNIVERSITY MEDICAL JOURNAL. 2011;11(2):165-178

The Role of Pharmacokinetics and Pharmacodynamics in Early Drug Development with reference to the Cyclin-dependent Kinase (Cdk) Inhibitor - Roscovitine.

Hassan M; Sallam H; Hassan Z
Article: EUROPEAN JOURNAL OF IMMUNOLOGY. 2011;41(4):1143-1153

N-acetyl-L-cysteine increases acute graft-versus-host disease and promotes T-cell-mediated immunity in vitro.

Karlsson H; Nava S; Remberger M; Hassan Z; Hassan M; Ringdén O
Article: TRANSPLANTATION. 2010;90(9):1022-1029

Granulocyte colony-stimulating factor induced acute and chronic graft-versus-host disease.

Ringden O; Hassan Z; Karlsson H; Olsson R; Omazic B; Mattsson J; Remberger M
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2010;84(4):323-331

GVHD prophylaxis using low-dose cyclosporine improves survival in leukaemic recipients of HLA-identical sibling transplants.

Olsson R; Remberger M; Hassan Z; Omazic B; Mattsson J; Ringdén O
Article: CLINICAL AND DEVELOPMENTAL IMMUNOLOGY. 2010;2010:142943-13

Expansion and activation kinetics of immune cells during early phase of GVHD in mouse model based on chemotherapy conditioning.

Sadeghi B; Al-Hashmi S; Hassan Z; Rozell B; Concha H; Lundmark C; Grönvik K-O; Abedi-Valugerdi M; Hassan M
Article: HLA. 2008;72(6):549-558

Outcome of haematopoietic stem cell transplantation in patients transplanted with matched unrelated donors vs allele-mismatched donors: a single centre study.

Hauzenberger D; Schaffer M; Ringdén O; Hassan Z; Omazic B; Mattsson J; Wikström A-C; Remberger M
Article: BONE MARROW TRANSPLANTATION. 2008;42(12):807-818

GVHD after chemotherapy conditioning in allogeneic transplanted mice.

Sadeghi B; Aghdami N; Hassan Z; Forouzanfar M; Rozell B; Abedi-Valugerdi M; Hassan M
Article: BONE MARROW TRANSPLANTATION. 2008;41(10):895-904

The effect of administration order of BU and CY on engraftment and toxicity in HSCT mouse model.

Sadeghi B; Jansson M; Hassan Z; Mints M; Hägglund H; Abedi-Valugerdi M; Hassan M
Article: BONE MARROW TRANSPLANTATION. 2008;41(9):785-790

A prospective randomized study using N-acetyl-L-cysteine for early liver toxicity after allogeneic hematopoietic stem cell transplantation.

Barkholt L; Remberger M; Hassan Z; Fransson K; Omazic B; Svahn B-M; Karlsson H; Brune M; Hassan M; Mattsson J; Ringdén O
Article: JOURNAL OF LIQUID CHROMATOGRAPHY & RELATED TECHNOLOGIES. 2008;31(5):683-694

Rapid and sensitive method for determination of cyclophosphamide in patients plasma samples utilizing microextraction by packed sorbent online with liquid chromatography-tandem mass spectrometry (MEPS-LC-MS/MS)

Said R; Hassan Z; Hassan M; Abdel-Rehim M
Article: BONE MARROW TRANSPLANTATION. 2008;41(4):399-405

Risk factors for acute graft-versus-host disease grades II-IV after reduced intensity conditioning allogeneic stem cell transplantation with unrelated donors: a single centre study.

Remberger M; Mattsson J; Hassan Z; Karlsson N; LeBlanc K; Omazic B; Okas M; Sairafi D; Ringdén O
Article: JOURNAL OF LIQUID CHROMATOGRAPHY & RELATED TECHNOLOGIES. 2007;30(20):3029-3041

Simultaneous determination of busulphan in plasma samples by liquid chromatography-electrospray ionization mass spectrometry utilizing microextraction in packed syringe (MEPS) as on-line sample preparation method

Abdel-Rehim M; Hassan Z; Skansem P; Hassan M
Article: CANCER CHEMOTHERAPY AND PHARMACOLOGY. 2007;60(6):841-849

Effect of the Cdk-inhibitor roscovitine on mouse hematopoietic progenitors in vivo and in vitro.

Song H; Vita M; Sallam H; Tehranchi R; Nilsson C; Sidén A; Hassan Z
Article: CLINICAL TRANSPLANTATION. 2007;21(5):659-667

Hemorrhagic cystitis: a retrospective single-center survey.

Hassan Z; Remberger M; Svenberg P; Elbander M; Omazic B; Mattsson J; Conrad R; Svahn B-M; Ahlgren A; Sairafi D; Aschan J; Le Blanc K; Barkholt L; Ringdén O
Article: CLINICAL CANCER RESEARCH. 2007;13(14):4218-4224

The effect of repeated administration of cyclophosphamide on cytochrome P450 2B in rats.

Afsharian P; Terelius Y; Hassan Z; Nilsson C; Lundgren S; Hassan M
Article: BONE MARROW TRANSPLANTATION. 2007;39(7):383-388

Fludarabine-based disease-specific conditioning or conventional myeloablative conditioning in hematopoietic stem cell transplantation for treatment of non-malignant diseases.

Ringdén O; Remberger M; Svenberg P; Svahn B-M; Dahllöf G; Gustafsson B; Hassan Z; Omazic B; Uzunel M; Aschan J; Barkholt L; Winiarski J; Ljungman P; Mattsson J
Article: TRANSPLANTATION. 2006;82(7):913-919

Unrelated versus related allogeneic stem cell transplantation after reduced intensity conditioning.

Uzunel M; Remberger M; Sairafi D; Hassan Z; Mattsson J; Omazic B; Barkholt L; Ringdén O
Article: TRANSPLANTATION. 2006;81(10):1390-1397

Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease.

Ringdén O; Uzunel M; Rasmusson I; Remberger M; Sundberg B; Lönnies H; Marschall H-U; Dlugosz A; Szakos A; Hassan Z; Omazic B; Aschan J; Barkholt L; Le Blanc K
Article: TRANSPLANTATION. 2006;81(5):718-725

Allogeneic hematopoietic stem cell transplantation for inherited disorders: experience in a single center.

Ringdén O; Remberger M; Svahn B-M; Barkholt L; Mattsson J; Aschan J; Le Blanc K; Gustafsson B; Hassan Z; Omazic B; Svenberg P; Solders G; von Döbeln U; Winiarski J; Ljungman P; Malm G
Article: EXPERIMENTAL HEMATOLOGY. 2006;34(1):115-121

Myeloablative and immunosuppressive properties of treosulfan in mice.

Sjöö F; Hassan Z; Abedi-Valugerdi M; Griskevicius L; Nilsson C; Remberger M; Aschan J; Concha H; Gaughan U; Hassan M
Article: EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES. 2006;27(1):54-61

Pharmacogenetics of cyclophosphamide in patients with hematological malignancies.

Xie H; Griskevicius L; Ståhle L; Hassan Z; Yasar U; Rane A; Broberg U; Kimby E; Hassan M
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2005;75(3):206-211

The effect of ciprofloxacin on cyclophosphamide pharmacokinetics in patients with non-Hodgkin lymphoma.

Afsharian P; Möllgård L; Hassan Z; Xie H; Kimby E; Hassan M
Article: JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES. 2005;821(1):75-80

Stability, pKa and plasma protein binding of roscovitine.

Vita M; Abdel-Rehim M; Nilsson C; Hassan Z; Skansen P; Wan H; Meurling L; Hassan M
Article: EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES. 2005;25(1):91-103

Tissue distribution, pharmacokinetics and identification of roscovitine metabolites in rat.

Vita M; Abdel-Rehim M; Olofsson S; Hassan Z; Meurling L; Sidén A; Sidén M; Pettersson T; Hassan M
Article: ANALYTICA CHIMICA ACTA. 2005;539(1-2):35-39

Microextraction in packed syringe/liquid chromatography/electrospray tandem mass spectrometry for quantification of olomoucine in human plasma samples

Abdel-Rehim M; Skansen P; Vita M; Hassan Z; Blomberg L; Hassan M
Article: EXPERIMENTAL HEMATOLOGY. 2005;33(3):380-387

Effect of altering administration order of busulphan and cyclophosphamide on the myeloablative and immunosuppressive properties of the conditioning regimen in mice.

Nilsson C; Forsman J; Hassan Z; Abedi-Valugerdi M; O'Connor C; Concha H; Jansson M; Hassan M
Article: BONE MARROW TRANSPLANTATION. 2003;32(4):349-354

N-acetyl-L-cysteine does not affect the pharmacokinetics or myelosuppressive effect of busulfan during conditioning prior to allogeneic stem cell transplantation.

Sjöö F; Aschan J; Barkholt L; Hassan Z; Ringdén O; Hassan M
Article: THERAPEUTIC DRUG MONITORING. 2003;25(3):400-406

On-line derivatization utilizing solid-phase microextraction (SPME) for determination of busulphan in plasma using gas chromatography-mass spectrometry (GC-MS).

Abdel-Rehim M; Hassan Z; Blomberg L; Hassan M
Article: BONE MARROW TRANSPLANTATION. 2002;30(12):833-841

A phase II trial of liposomal busulphan as an intravenous myeloablative agent prior to stem cell transplantation: 500 mg/m(2) as a optimal total dose for conditioning.

Hassan M; Nilsson C; Hassan Z; Gungor T; Aschan J; Winiarski J; Hentschke P; Ringdén O; Eber S; Seger R; Ljungman P
Article: BONE MARROW TRANSPLANTATION. 2002;30(3):141-147

The effect of modulation of glutathione cellular content on busulphan-induced cytotoxicity on hematopoietic cells in vitro and in vivo.

Hassan Z; Hellström-Lindberg E; Alsadi S; Edgren M; Hägglund H; Hassan M
Article: BONE MARROW TRANSPLANTATION. 2001;28(7):657-664

Population pharmacokinetic analysis resulting in a tool for dose individualization of busulphan in bone marrow transplantation recipients.

Sandström M; Karlsson MO; Ljungman P; Hassan Z; Jonsson EN; Nilsson C; Ringden O; Oberg G; Bekassy A; Hassan M
Article: LEUKEMIA. 2001;15(8):1240-1247

The pharmacodynamic effect of busulfan in the P39 myeloid cell line in vitro.

Hassan Z; Hassan M; Hellström-Lindberg E
Article: BONE MARROW TRANSPLANTATION. 2001;27(5):479-485

Pharmacokinetics of liposomal busulphan in man.

Hassan Z; Ljungman P; Ringdén O; Winiarski J; Nilsson C; Aschan J; Whitley HR; Hassan M
Article: BONE MARROW TRANSPLANTATION. 2000;25(9):915-924

The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicity.

Hassan M; Ljungman P; Ringdén O; Hassan Z; Oberg G; Nilsson C; Békassy A; Bielenstein M; Abdel-Rehim M; Georén S; Astner L
Article: EXPERIMENTAL HEMATOLOGY. 1999;27(8):1322-1329

Two pathways of apoptosis induced with all-trans retinoic acid and etoposide in the myeloid cell line P39.

Hassan Z; Fadeel B; Zhivotovsky B; Hellström-Lindberg E
Article: LEUKEMIA. 1999;13(5):719-728

Cleavage of Bcl-2 is an early event in chemotherapy-induced apoptosis of human myeloid leukemia cells.

Fadeel B; Hassan Z; Hellström-Lindberg E; Henter JI; Orrenius S; Zhivotovsky B
Article: BONE MARROW TRANSPLANTATION. 1998;22(9):913-918

Liposomal busulphan: bioavailability and effect on bone marrow in mice.

Hassan Z; Nilsson C; Hassan M
Article: CANCER CHEMOTHERAPY AND PHARMACOLOGY. 1998;42(6):471-478

Pharmacokinetics and distribution of liposomal busulfan in the rat: a new formulation for intravenous administration.

Hassan M; Hassan Z; Nilsson C; Rehim MA; Kumlien S; Elfsson B; Kållberg N
Article: BONE MARROW TRANSPLANTATION. 1996;18(5):843-850

Busulphan kinetics and limited sampling model in children with leukemia and inherited disorders.

Hassan M; Fasth A; Gerritsen B; Haraldsson A; Syrůcková Z; van den Berg H; Sandström M; Karlsson M; Kumlien S; Vossen J
Article: PEDIATRIC HEMATOLOGY AND ONCOLOGY. 1996;13(2):143-150

Infection-associated hemophagocytic syndrome complicated by infectious lymphoproliferation: a case report.

Syrůcková Z; Starý J; Sedlácek P; Smísek P; Vavrinec J; Komrska V; Roubalová K; Vandasová J; Sintáková B; Housková J; Hassan M
Show more

All other publications

Review: PEDIATRIC TRANSPLANTATION. 2011;15(4):348-361

Management of refractory hemorrhagic cystitis following hematopoietic stem cell transplantation in children.

Hassan Z
Meeting abstract: TRANSPLANTATION AND CELLULAR THERAPY. 2011;17(2):S345

DYNAMICS OF DONOR T CELL ACTIVATION DURING EARLY PHASE OF GRAFT VERSUS HOST DISEASE (GVHD): DONOR ANTIGEN PRESENTING CELLS CAN ACTIVATE ALLOGENEIC T CELLS

Sadeghi B; Al-Hashmi S; Hassan Z; Hassan M
Editorial comment: PEDIATRIC TRANSPLANTATION. 2010;14(6):683-687

Optimal approach to prevent veno-occlusive disease following hematopoietic stem cell transplantation in children.

Hassan Z
Meeting abstract: TRANSPLANTATION AND CELLULAR THERAPY. 2009;15(2):59

GVHD PROPHYLAXIS USING LOW-DOSE CYCLOSPORINE IS SAFE AND REDUCES THE RISK OF RELAPSE AND DEATH IN LEUKEMIC RECIPIENTS OF HLA-IDENTICAL SIBLING TRANSPLANTS

Olsson R; Remberger M; Mattsson J; Hassan Z; Ringden O
Meeting abstract: TRANSPLANTATION AND CELLULAR THERAPY. 2009;15(2):127

N-ACETYL-L-CYSTEINE PROMOTES T CELL MEDIATED IMMUNITY IN ALLOGENEIC SETTINGS IN VIVO AND IN VITRO

Karlsson H; Nava S; Remberger M; Hassan Z; Hassan M; Ringden O
Meeting abstract: BLOOD. 2006;108(11):97A

Effect of busulphan dose adjustment on regimen-related toxicity.

Hassan Z; Remberger M; Ringden O; Oberg G; Bekassy AN; Hassan M
Meeting abstract: TRANSPLANTATION AND CELLULAR THERAPY. 2006;12(2):2

Mesenchymal stem cells for treatment of severe acute graft-versus-host disease

Ringden O; Uzunel M; Rasmusson I; Remberger ME; Sundberg B; Lonnies H; Marschall HU; Dlugosz A; Szakos A; Hassan Z; Omazic B; Aschan J; Barkholt L; Le Blanc K

Employments

Affiliated to Teaching/Tutoring, Department of Laboratory Medicine, Karolinska Institutet, 2022-2025

Degrees and Education

Docent, Karolinska institutet, 2009
Doctor Of Philosophy, Department of Medicine, Huddinge, Karolinska Institutet, 2001

Articles

All other publications

Employments

Degrees and Education

News from KI

Events from KI